Patients with ovarian cancer are at increased risk of venous thromboembolism (VTE), and the cumulative incidence is high, particularly at advanced stages of this disease. Nevertheless, it is challenging to investigate the molecular mechanisms of ovarian cancer–associated VTE (OC-VTE), mainly due to the lack of a well-developed animal model for this disease. We generated a mouse model for developing OC-VTE using ovarian cancer cell injection in combination with the inferior vena cava stenosis method. The rate of thrombosis in the OC-VTE group was 50%, compared with 0 in the control group. Moreover, we conducted a proteomic analysis using platelets from these models and revealed differentially expressed proteins between the OC-VTE and control groups, including upregulated and downregulated proteins. Gene Ontology analysis revealed that these differentially expressed proteins were mostly enriched in the biological process of negative regulation of fibrinolysis and the cellular component of the fibrinogen complex, both of which play key roles in thrombosis. In conclusion, this study lays the foundation for further investigation of the underlying mechanisms of how ovarian cancer promotes VTE formation.
KisselevaTBrennerD.Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol2021;18:151–66
2.
FargeDFrereCConnorsJMAyCKhoranaAAMunozABrennerBKakkarARafiiHSolymossSBrilhanteDMonrealMBounameauxHPabingerIDouketisJ, International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol2019;20:e566–81
3.
WatsonHGKeelingDMLaffanMTaitRCMakrisM, British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis.Br J Haematol2015;170:640–8
4.
KeyNSKhoranaAAKudererNMBohlkeKLeeAYYArcelusJIWongSLBalabanEPFlowersCRFrancisCWGatesLEKakkarAKLevineMNLiebmanHATemperoMALymanGHFalangaA.Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol2020; 38:496–520
5.
SorensenHTMellemkjaerLOlsenJHBaronJA.Prognosis of cancers associated with venous thromboembolism.N Engl J Med2000;343: 1846–50
6.
KhoranaAAFrancisCWCulakovaEKudererNMLymanGH.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.J Thromb Haemost2007;5:632–4
7.
FargeDBounameauxHBrennerBCajfingerFDebourdeauPKhoranaAAPabingerISolymossSDouketisJKakkarA.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol2016;17:e452–66
8.
LymanGHCulakovaEPoniewierskiMSKudererNM.Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer.Thromb Res2018;164:S112–8
9.
Strom KahrHChristiansenOBJuul RiddersholmSGadeILTorp-PedersenCKnudsenAThorlacius-UssingO.The timing of venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study.J Thromb Haemost2021;19:992–1000
10.
SatohTOkiAUnoKSakuraiMOchiHOkadaSMinamiRMatsumotoKTanakaYOTsunodaHHommaSYoshikawaH.High incidence of silent venous thromboembolism before treatment in ovarian cancer.Br J Cancer2007;97:1053–7
FalatiSLiuQGrossPMerrill-SkoloffGChouJVandendriesECeliACroceKFurieBCFurieB.Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.J Exp Med2003;197:1585–98
13.
BrillAFuchsTAChauhanAKYangJJDe MeyerSFKollnbergerMWakefieldTWLämmleBMassbergSWagnerDD.von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models.Blood2011;117:1400–7
14.
DiazJAObiATMyersDDJrWrobleskiSKHenkePKMackmanNWakefieldTW.Critical review of mouse models of venous thrombosis.Arterioscler Thromb Vasc Biol2012;32:556–62
15.
WangXSmithPLHsuMYTamasiJABirdESchumacherWA.Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.J Thromb Thrombolysis2007;23:41–9
16.
HerbertJMBernatAMaffrandJP.Importance of platelets in experimental venous thrombosis in the rat.Blood1992;80:2281–6
17.
MyersDJrFarrisDHawleyAWrobleskiSChapmanAStoolmanLKnibbsRStrieterRWakefieldT.Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis.J Surg Res2002;108:212–21
18.
von BruhlMLStarkKSteinhartAChandraratneSKonradILorenzMKhandogaATirniceriuAColettiRKöllnbergerMByrneRALaitinenIWalchABrillAPfeilerSManukyanDBraunSLangePRieggerJWareJEckartAHaidariSRudeliusMSchulzCEchtlerKBrinkmannVSchwaigerMPreissnerKTWagnerDDMackmanNEngelmannBMassbergS.Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.J Exp Med2012;209:819–35
19.
DiazJASahaPCooleyBPalmerORGroverSPMackmanNWakefieldTWHenkePKSmithALalBK.Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application.J Thromb Haemost2019;17:699–707
20.
HisadaYMackmanN.Mouse models of cancer-associated thrombosis.Thromb Res2018;164:S48–53
21.
TimpJFBraekkanSKVersteegHHCannegieterSC.Epidemiology of cancer-associated venous thrombosis.Blood2013;122:1712–23
22.
WangJGGeddingsJEAlemanMMCardenasJCChantrathammachartPWilliamsJCKirchhoferDBogdanovVYBachRRRakJChurchFCWolbergASPawlinskiRKeyNSYehJJMackmanN.Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.Blood2012;119:5543–52
23.
SinghSHoungAKReedGL.Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of alpha2-antiplasmin.Blood2019; 134:970–8
24.
AbdulSLeebeekFWRijkenDCUittedeWilligeS.Natural heterogeneity of alpha2-antiplasmin: functional and clinical consequences.Blood2016;127:538–45
25.
VogelGMMeulemanDGBourgondienFGHobbelenPM.Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.Thromb Res1989;54:399–410
26.
WesslerS.Thrombosis in the presence of vascular stasis.Am J Med1962;33:648–66
27.
WesslerSGitelSNBankHMartinowitzUStephensonRC.An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits.Thromb Haemost1979;40:486–98
28.
AlbadawiHWittingAAPershadYWallaceAFleckARHoangPKhademhosseiniAOkluR.Animal models of venous thrombosis.Cardiovasc Diagn Ther2017;7:S197–206
29.
BernatAValleeEMaffrandJPRoncucciR.Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.Thromb Res1985;37:279–85
30.
DoutremepuichCGestreauJLMauryMOQuilichiniRBoisseauMRToulemondeFVairelE.Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction.Haemostasis1983;13:109–12
31.
ThomasDPMertonREHockleyDJ.The effect of stasis on the venous endothelium: an ultrastructural study.Br J Haematol1983;55:113–22
32.
BrillAFuchsTASavchenkoASThomasGMMartinodKDe MeyerSFBhandariAAWagnerDD.Neutrophil extracellular traps promote deep vein thrombosis in mice.J Thromb Haemost2012;10:136–44
